SPOP and prostate cancer: In the context of hypoxia-driven pathways, EGLN2 (egl-9 family hypoxia-inducible factor 2), a key regulator of cellular adaptation to low oxygen, shows elevated expression in prostate cancer, and its ubiquitination by the tumor suppressor SPOP constrains cancer cell growth [47].